Yong Wu

Title(s)Associate Adjunct Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Yong Wu, M.D., Ph.D., holds faculty positions at David Geffen School of Medicine at the University of California, Los Angeles (UCLA). He is also an Associate Professor and Core Director for the Drug Discovery Program in Charles Drew University of Medicine and Science. Dr. Wu has a broad background in pharmacology, molecular and cellular biology of diabetes and cancer, and has experiences in anti-cancer drug design and discovery. He is a member of the American Association for Cancer Research and American Heart Association, among others.
    Currently, He is engaged in investigating the links between metabolic syndrome and cancer, specifically focusing on the fundamental mechanisms by which elevated blood glucose and fatty acids increase breast cancer risk and progression. This is a key area of interest in the Division of Cancer Research and Training. His current research has also been focused on (1) elucidating a safe and effective therapeutic strategy to preferentially kill the malignant cells that are dependent on glycolytic pathway with a minor effect on normal cells; (2) Design, synthesis, modification, and biological evaluation of small molecule anti-cancer compounds for breast cancer therapeutic development.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Brief Advice, Nicotine Replacement Therapy Sampling, and Active Referral for Expectant Fathers Who Smoke Cigarettes: A Randomized Clinical Trial. JAMA Intern Med. 2021 Aug 01; 181(8):1081-1089. Luk TT, Lam TH, Leung WC, Leung KY, Cheung KW, Kwa C, Siong KH, Tang KK, Lee KW, Hsieh CJ, Wu YS, Li WH, Wang MP. PMID: 34125135.
      View in: PubMed   Mentions:    Fields:    
    2. Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer. Journal of Cancer Science and Clinical Therapeutics 5 (2021): 134-153. 2021. .
    3. Basal-like breast cancer with low TGFβ and high TNFα pathway activity is rich in activated memory CD4 T cells and has a good prognosis. Int J Biol Sci. 2021 Jan 30;17(3):670-682. doi: 10.7150/ijbs.56128. eCollection 2021. 2021. Liu D, Vadgama J, Wu Y.
    4. Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA. Cell Death Dis. 2020 Dec 11;11(12):1052. doi: 10.1038/s41419-020-03235-w. PMID: 33311440; PMCID: PMC7733521. 2021. 4. Hao Q, Wang P, Dutta P, Chung S, Li Q, Wang K, Li J, Cao W, Deng W, Geng Q, Schrode K, Shaheen M, Wu K, Zhu D, Chen QH, Chen G, Elshimali Y, Vadgama J, Wu Y.
    5. Association of an anaplastic lymphoma kinase pathway signature with cell de-differentiation, neoadjuvant chemotherapy response, and recurrence risk in breast cancer. Cancer Commun (Lond). 2020 Sep;40(9):422-434. doi: 10.1002/cac2.12038. Epub 2020 Aug 21. PMID: 32822101; PMCID: PMC7494065. 2021. Liu D, Wu Y*.
    6. The role of PPM1D in cancer and advances in studies of its inhibitors. Biomed Pharmacother. 2020 Jan 29;125:109956. doi: 10.1016/j.biopha.2020.109956. [Epub ahead of print]. PMID: 32006900. 2021. Deng W, Li J, Dorrah K, Jimenez-Tapia D2 Arriaga B, Hao Q, Cao W, Gao Z, Vadgama J, Wu Y*.
    7. PP2Cδ inhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNA damage response. Sci Adv. 2019 Oct 16;5(10):eaaw8417. doi: 10.1126/sciadv.aaw8417. eCollection 2019 Oct. (PMCID: PMC6795508). 2021. Li Q, Hao Q, Cao W, Li J, Wu K, Elshimali Y, Zhu D, Chen Q, Chen G, Pollack J, Vadgama JV, and Wu Y*.
    8. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. Breast Cancer Res. 2019 Feb 21;21(1):29. doi: 10.1186/s13058-019-1107-2. (*corresponding author) (PMCID: PMC6385460). 2021. Cao W, Li J, Hao Q, Vadgama JV*, Wu Y*.
    9. Targeting of PP2cδ By A Small Molecule C23 Inhibits High Glucose-Induced Breast Cancer Progression In Vivo. Antioxid Redox Signal. 2019 Jun 10;30(17):1983-1998. (*corresponding author) (PMCID: PMC6486665). 2021. Wu K, Yu X, Huang Z, Zhu D, Yi X, Wu YL, Hao Q, Kemp KT 2nd, Elshimali Y, Iyer R, Nguyen KT, Zheng S, Chen G, Chen QH, Wang G, Vadgama JV, Wu Y*.
    10. Mobile chat-based support plus nicotine replacement therapy sampling to promote smoking cessation for community smokers: A randomized controlled trial. Tob Induc Dis. 2021; 19:32. Zhao SZ, Wu YS, Chau SL, Fong DYT, Lam TH, Wang MP. PMID: 33927586.
      View in: PubMed   Mentions:
    11. Association of heated tobacco product use with smoking cessation in Chinese cigarette smokers in Hong Kong: a prospective study. Tob Control. 2020 Sep 10. Luk TT, Weng X, Wu YS, Chan HL, Lau CY, Kwong AC, Lai VW, Lam TH, Wang MP. PMID: 32912861.
      View in: PubMed   Mentions: 1     Fields:    
    12. Exposure to health misinformation about COVID-19 and increased tobacco and alcohol use: a population-based survey in Hong Kong. Tob Control. 2020 Aug 27. Luk TT, Zhao S, Weng X, Wong JY, Wu YS, Ho SY, Lam TH, Wang MP. PMID: 32855353.
      View in: PubMed   Mentions: 11     Fields:    
    13. Positive perceptions of electronic cigarettes relative to combustible cigarettes are associated with weaker support for endgame policies on combustible cigarettes: A population-based cross-sectional study in Hong Kong. Tob Induc Dis. 2019; 17:61. Wu YS, Wang MP, Ho SY, Cheung YT, Kwong A, Lai V, Lam TH. PMID: 31582950.
      View in: PubMed   Mentions:
    14. Heated tobacco products use in Chinese adults in Hong Kong: a population-based cross-sectional study. Tob Control. 2020 05; 29(3):277-281. Wu YS, Wang MP, Ho SY, Li HCW, Cheung YTD, Tabuchi T, Kwong AC, Lai V, Lam TH. PMID: 31005892.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    15. Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res. 2017 03 15; 77(6):1383-1394. Wu Y, Yu X, Yi X, Wu K, Dwabe S, Atefi M, Elshimali Y, Kemp KT, Bhat K, Haro J, Sarkissyan M, Vadgama JV. PMID: 28115363.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    16. Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing. Breast Cancer Res Treat. 2015 Jun; 151(3):529-39. Wu Y, Sarkissyan M, Mcghee E, Lee S, Vadgama JV. PMID: 25975952.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    Yong's Networks
    Concepts (58)
    Derived automatically from this person's publications.
    _
    Co-Authors (1)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _